Navigation Links
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
Date:1/26/2009

xacin is a novel, broad spectrum, next-generation fluoroquinolone, that is more active than other quinolones against Gram-positive bacteria, including isolates of MRSA that are resistant to other quinolones. In large panel microbiological testing, the compound has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin against quinolone-resistant MRSA (MIC90 of less than or equal to 0.5 micrograms/mL for delafloxacin versus > 16 micrograms/mL for all other quinolones). Currently in development as an intravenous formulation, delafloxacin has also been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic and Gram-negative organisms. Rib-X is interested in developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic arenas within the over $9.9 billion hospital antibiotic market.(1)

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to delafloxacin, Rib-X is currently in Phase 2 tria
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
2. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
6. Axikin Pharmaceuticals Spins out of Actimis
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Cumberland Pharmaceuticals Appoints Lee Product Director
10. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
11. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... biopharmaceutical contract development and manufacturing organization (CMO) announced ... Pharmaceuticals, Inc., an oncology company focused on the ... cancer, to manufacture the anti-prostate specific membrane antigen ... product candidate. Under the agreement the antibody ...
(Date:8/20/2014)... university inventions licensed to biotechnology firms has revealed ... open these roadblocks, the researchers suggest that better ... stage could lead to faster commercialization down the ... discoveries made in university laboratories and licensed to ... trials, which have a high failure rate. But ...
(Date:8/20/2014)... High performance computing (HPC) will ... complete climate and Earth system model to address ... , Eight national laboratories, including Lawrence Livermore ... for Atmospheric Research, four academic institutions and one ... national laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Health-focused social networks,blogs, wikis and community sites ... can be their biggest opportunities. A marketing,executive ... increasing,importance of reputation monitoring and management in ... Generated Content and Enhancing its Impact,on Your ...
... EASTON, Mass., Dec. 11 Pressure BioSciences, Inc. (Nasdaq: ... Omni International ("Omni") today announced that they have entered ... Under the terms of the Agreement, the companies will: ... competitive information; (2) co-promote certain products at industry trade ...
... adults may be familiar with the,tetanus and diphtheria booster ... a booster shot that protects adolescents and adults from,whooping ... Listen to this report from ... Registered journalists can access video, audio, text, ...
Cached Biology Technology:Exclusive Conference on Managing Your Online Brand: Shaping the Noise from the Blogosphere 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 2Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 3Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 4Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement 5
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... a chili pepper causes a burning spiciness that is ... the chili pepper,s effect are using their findings to ... pain, which can be caused by inflammation or other ... is being tested in clinical trials, in ACS, ... colleagues explain that decades ago, scientists had pegged a ...
(Date:8/20/2014)... (August 20, 2014) Women who are poor experience ... infants with elevated levels of the stress hormone, ... in life, according to a new research from the ... recently in the American Journal of Human Biology ... and relate it directly to the socioeconomic status of ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2CU Denver researcher shows economic disparities impact infant health 2
... Ohio, June 27, 2012 Expertise in fluid mechanics at ... research center designed to help physicians better diagnose and treat ... shoulders. Chiari malformation is a disorder of the neurologic ... spinal fluid. UA engineers are able to probe the ...
... is a very small unit, even smaller than the nano ... Alonso has devoted himself to studying green algae of this ... to the area beyond the Nervin estuary. This has enabled ... species that until now had not been catalogued in these ...
... Anatolian Neolithic" is the name of a new multinational ... Commission for the next four years. It is classified ... EU Marie Curie Actions program, which allows young scientists ... A basic requirement for funding is that the researchers ...
Cached Biology News:When does a headache need an engineer to fix it? 2When does a headache need an engineer to fix it? 3A nanoscopic look at the estuary's green algae 2A nanoscopic look at the estuary's green algae 3Mainz University coordinates new EU project on the origins of human settlement 2Mainz University coordinates new EU project on the origins of human settlement 3
... kit contains 5 ml CELLection Dynabeads (4.5 ... the human epithelial antigen EpCAM and DNase ... log enrichment of epithelial tumour cells directly ... cells clumps can be enriched from bone ...
nucleophosmin (nucleolar phosphoprotein B23, numatrin), mRNA...
Human PDGF R beta MAb (Clone # PR7212)...
... Ambion's ActivePro In Vitro ... an E.coli lysate, synthesizes ... as well as proteins ... than competing kits. This ...
Biology Products: